Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

February 28, 2011

Conditions
Keratoconjunctivitis SiccaDry Eye
Interventions
DRUG

rebamipide 2% ophthalmic suspension

Instill one drop in each eye four times daily for 12 weeks.

DRUG

placebo eye drops

Instill one drop in each eye four times daily for 12 weeks.

Trial Locations (19)

11030

New York Ophthalmology, PC, Manhasset

28204

Mundorf Eye Center, Charlotte

33143

Med Eye Associates, Miami

33426

Florida Eye Microsurgical Institute, Inc., Boynton Beach

33431

Cohen Laser and Vision Center, Boca Raton

40205

George R. John, MD, Louisville

57701

Black Hills Regional Eye Institute, Rapid City

63131

Ophthalmology Associates, St Louis

79902

The Cataract & Glaucoma Center, El Paso

80120

Corneal Consultants of Colorado, Littleton

80134

Specialty Eye Care, Parker

85003

Arizona Center for Clinical Trials, LLC, Phoenix

85032

Cornea Consultants of Arizona, Phoenix

85206

East Valley Ophthalmology, Mesa

89119

Nevada Eye Care Professionals, Las Vegas

89131

Avista Eye Center, Las Vegas

90048

Macy Eye Center, Los Angeles

04240

Central Maine Eye Care, Lewiston

01810

Ora, Inc., Andover

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kubota Vision Inc.

INDUSTRY